Share Name Share Symbol Market Type Share ISIN Share Description
Tekcapital LSE:TEK London Ordinary Share GB00BKXGY798 ORD £0.004
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 36.25p 35.50p 37.00p 36.25p 36.25p 36.25p 0.00 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Technology Hardware & Equipment 0.3 -1.0 -3.3 - 15.46

Tekcapital Share Discussion Threads

Showing 401 to 422 of 425 messages
Chat Pages: 17  16  15  14  13  12  11  10  9  8  7  6  Older
DateSubjectAuthorDiscuss
03/3/2017
10:11
4 announcements in one week! Let's hope all these product launches lead to increased revenues & profits in due course so that the company doesn't have to continue relying on tapping the markets to fund itself. "Monsieur Gross. With zeese announcements, you are really spoiling us" [said in best Ferrer Rocher accent] - HTTPS://youtu.be/hMlP_Moo0bE
speedsgh
03/3/2017
07:45
RNS RNS Number : 4031Y Tekcapital plc 03 March 2017  3 March 2017 Tekcapital plc ("Tekcapital" or the "Company") BELLUSCURA LTD LAUNCHES PASSPORT® DISPOSABLE TROCAR IN USA Tekcapital plc (AIM: TEK), an international provider of technology and intellectual property services, announces that Belluscura Ltd ("Belluscura") has launched Passport® in the United States. Passport is a disposable trocar used in laparoscopic, or 'keyhole' surgery, and features the patented SmartTip™ technology, designed to be compatible with the Da Vinci®1 S and Si robotic surgical systems. Passport, with its unique seal, is used as the access point for the endoscope camera which allows the surgeon to visualise the procedure site. The SmartTip controls the cutting blade to prevent accidental deployment inside the patient and potential tissue damage. It is estimated that more than 7.5 million laparoscopic procedures are performed annually2, with 2.8 million being performed in the US alone. Laparoscopic procedures continue to replace more invasive surgery because of the faster recovery, lower surgical headcount requirement and better training.3 Please click here for picture of Passport® http://www.rns-pdf.londonstockexchange.com/rns/4031Y_-2017-3-2.pdf Bob Rauker, Belluscura's CEO said: "The launch of this Passport trocar provides Belluscura with a presence in the surgical device field. Passport is the first of a family of trocars and cannulae that Belluscura will seek to launch over the coming years. Together, these will form a range of products to support surgeons in an array of specialties." About Belluscura: Belluscura Limited is a global medical device company founded in Oxford, England. Its mission is to make healthcare more affordable for patients and their providers by providing proprietary medical devices across a wide variety of treatment and diagnostic disciplines. Belluscura's products were originally developed by leading medical device companies or research centres, and with its unique business model it is able to offer these devices at affordable prices. To learn more about Belluscura please visit www.belluscura.com. Tekcapital owns approximately 65% of the share capital of Belluscura.
dynam1te
02/3/2017
07:55
Belluscura Ltd Launches Slyde in EU RNS RNS Number : 2739Y Tekcapital plc 02 March 2017 2 March 2017 Tekcapital plc ("Tekcapital" or the "Company") BELLUSCURA LTD LAUNCHES SLYDE™ IN EU Tekcapital plc (AIM: TEK), an international provider of technology and intellectual property services, announces that Belluscura Ltd ("Belluscura") has launched its Slyde product in the European Union. Slyde is a light and compact sled for moving its occupant safely down stairs or over rough ground in the event of an emergency evacuation. It provides a safe and efficient way to evacuate non-ambulatory individuals from any multi-storey building using the stairways. Slyde folds up and stores in stacks of up to five units in a storage sleeve. The sleeve can be wall-mounted for quick access in key locations. Slyde is sold in two sizes with a range of accessories designed to safely lower people in the event of an emergency evacuation. Stephen Appelbee, Belluscura's International Director of Global Sales said: "We are delighted to make this important step towards becoming a truly international medical device company. Our first product, Slyde, is a good example of Belluscura's mission to provide premium medical device products at affordable prices, and we expect it to be widely adopted by hospitals, schools, hotels and rescue services. We intend to use the expertise of local distributors in each region, starting in the European Union." Slyde is already available and selling in the USA. About Belluscura: Belluscura Limited is a global medical device company founded in Oxford, England. Its mission is to make healthcare more affordable for patients and their providers by providing proprietary medical devices across a wide variety of treatment and diagnostic disciplines. Belluscura's products were originally developed by leading medical device companies or research centres, and with its unique business model it is able to offer these devices at affordable prices. To learn more about Belluscura please visit www.belluscura.com. Tekcapital owns approximately 65% of the share capital of Belluscura.
dynam1te
01/3/2017
08:06
Belluscura Ltd Launches Wire CaddyT In USA RNS RNS Number : 1208Y Tekcapital plc 01 March 2017 1 March 2017 Tekcapital plc ("Tekcapital" or the "Company") BELLUSCURA LTD LAUNCHES WIRE CADDY™ IN USA Tekcapital plc (AIM: TEK), an international provider of technology and intellectual property services, announces that Belluscura Ltd ("Belluscura") has launched its Wire Caddy™ product in the United States. The Wire Caddy™ is an innovative wire management system that provides lubrication and organization during multi-wire, multi-exchange operating room cases, such as cardiology interventions, uterine fibroid embolizations and tibial angioplasties. The Wire Caddy™ was designed by interventional radiologist Dr Shaun Samuels to address unique challenges in complex surgical procedures, especially those involving multi-wire and multi-exchange cases. Its unobtrusive positioning allows quick access to lubricated guidewires during surgical procedures in interventional radiology, catheterization laboratory, vascular suite and other operating room operations. Belluscura's Wire Caddy™ is particularly useful for single operators, interventional radiology trainees, fellows and residents. Belluscura's Chief Executive Officer Bob Rauker said: "Wire Caddy™ is an excellent component in our product portfolio, which offers premium and affordable solutions to meet the needs of the patient and healthcare providers". About Belluscura: Belluscura Limited is a global medical device company founded in Oxford, England. Its mission is to make healthcare more affordable for patients and their providers by providing proprietary medical devices across a wide variety of treatment and diagnostic disciplines. Belluscura's products were originally developed by leading medical device companies or research centres, and with its unique business model it is able to offer these devices at affordable prices. To learn more about Belluscura please visit www.belluscura.com. Tekcapital owns approximately 65% of the share capital of Belluscura. For further information, please contact: Tekcapital Plc Clifford M. Gross, Ph.D. info@tekcapital.com Allenby Capital Limited (Nominated Adviser & Joint Broker) +44 (0) 20 3328 5656 Jeremy Porter / Alex Brearley Dowgate Capital Stockbrokers (Joint Broker) +44 (0) 1293 517744 David Poutney / James Serjeant Walbrook PR Ltd +44 (0) 20 7933 8780 Paul Cornelius / Helen Cresswell / Sam Allen tekcapital@walbrookpr.com Tekcapital plc - The World's Largest University Network for Open Innovation Tekcapital helps clients profit from new, university-developed intellectual properties. With its proprietary discovery search engine, linked to 4,500+ universities in 160 countries, coupled with expert scientific review, Tekcapital provides a turn-key service to make it easy for clients to find and acquire the IP, analytics and technology transfer professionals they need to create a competitive advantage. Tekcapital plc is quoted on the AIM market of the London Stock Exchange (AIM: symbol TEK) and is headquartered in Oxford, in the UK. For more information, please visit www.tekcapital.com LEI: 213800GOJTOV19FIFZ85
dynam1te
26/1/2017
19:13
Yes, perversely, well done on the placing LOL +8% is not to be sniffed at. I have no clue how to value Belluscura BB2, but what are the odds on it IPO and then signing a deal for crackle bake and walking electricity with TEK? Im probably being unfair, and whilst TEK is still on my w/l, Im starting to get a bad feel for it. They are not doing what they said they would do, and the goal posts are moving, what happened to the 18 month target to get a licence? Gone and forgotten? Its now long term?
pj 1
26/1/2017
17:15
Going by today's share price action, TEK perhaps ought to do placings more often! ;o)
speedsgh
26/1/2017
13:17
Yes great call PJ, not sure why the shares are higher today but I'm not complaining. Any ideas on value of Belluscura?
battlebus2
26/1/2017
09:08
PJ 14 Jan '17 - 08:10 - 388 of 393 0 0 Edit Nice to see positive news. No contract yet. Beware a pump before a placing!
pj 1
26/1/2017
09:06
So Belluscura has burnt through $2million already?
pj 1
26/1/2017
09:01
So the long-awaited placing rns has arrived this morning. Looking to raise up to £2.4m (not less than £1m) at 35p. The market seems to have taken the news as mildly positive at present. Proposed placing to raise gross proceeds of up to approximately £2.4 million - HTTP://www.investegate.co.uk/tekcapital-plc--tek-/rns/proposed-placing/201701260700101485V/ Use of Proceeds The Company intends that the net proceeds of the Placing will be predominantly used to: · launch IP-related software applications; · expand the Company's sales programme in Latin America; · acquire and market new intellectual properties; and · for general working capital purposes. Some useful titbits under 'Background to the Placing'... re possible Belluscura IPO in 2017 - "The Company is currently exploring an IPO of Belluscura in 2017. If this IPO proceeds, then the Directors believe that this should represent a value inflexion point for Tekcapital's shareholders." "The Board believes that the Company would benefit from additional finance to enable it to accelerate its growth strategy. The Placing is expected to allow the Company to continue to fund acquisitions of additional new potentially disruptive university intellectual properties, and complete further out-licenses of intellectual properties that are already under exclusive license to Tekcapital, several of which are currently in negotiation. The Board believes that this strategy, coupled with the future growth of sustainable income streams from corporate services, out-licenses, and the potential IPO of Belluscura, should facilitate the creation of material shareholder value over the LONGER term." Interesting that they appear to see a possible Belluscura IPO, and not the out-licensing of the much-vaunted Crackle-baked process, as the main catalyst for increasing shareholder value.
speedsgh
04/1/2017
09:39
TEK RNS covered by Trader Tim this morning, good analysis! Price is key with this one. http://buff.ly/2j3zCTL
mikeroot5
04/1/2017
08:20
Hopefully, would certainly be a first in 2017!
pj 1
04/1/2017
08:13
Yes good to see, what a placing we shareholders may participate in....
battlebus2
04/1/2017
08:10
Nice to see positive news. No contract yet. Beware a pump before a placing!
pj 1
28/12/2016
11:23
Yes it is progress, hopefully they have more success and we can see a good return from the 5% royalties.
battlebus2
31/10/2016
08:05
Initial reaction. Latin America? MIRA? Confirms the changing strategy IMO, wonder why they have not communicated it to Investors more pro-actively? Maybe VOX Markets says it all
pj 1
30/10/2016
15:51
London buses, bb ;-)
speedsgh
28/10/2016
13:15
It'll happen RP19, sooner rather than later imv :))
battlebus2
28/10/2016
12:50
From the half year interims - "By the end of the year (November 2016) we expect to make significant out-license progress". Getting towards time to deliver.
rp19
28/10/2016
07:37
Crackle bake making progress with second patent allowance.
battlebus2
25/10/2016
08:03
Private placing Nigel Wray inc for Belluscura..
battlebus2
12/10/2016
17:52
Yes. Very interesting move today. Watching more closely now
pj 1
Chat Pages: 17  16  15  14  13  12  11  10  9  8  7  6  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20170430 03:15:04